CytoTools AG together with its licensing partner Centaur Pharmaceuticals, has achieved a good start to the marketing of its active ingredient for the treatment of diabetic foot syndrome in India. The market launch of the drug, which is marketed in India under the brand name Woxheal(R), was clearly overshadowed by the high prevalence of COVID-19 in India and the associated travel restrictions. However, given the severely limited opportunities to market the new drug through on-site sales appointments, the number of treatments performed is very promising.